All Stories

  1. Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach

    Article • Current Pharmaceutical Design, December 2019, Bentham Science Publishers

    Professor M Isabel Lucena, Inma Medina

  2. The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury

    Article • Liver International, September 2018, Wiley

    Professor M Isabel Lucena

  3. Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus

    Article • Clinical Pharmacology & Therapeutics, September 2017, Wiley

    Professor M Isabel Lucena, Mats Bengtsson

  4. Drug‐induced liver and skin reactions: In need of a consensus definition

    Article • Hepatology, October 2016, Wiley

    Professor M Isabel Lucena

  5. Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis

    Article • Pharmacogenetics and Genomics, September 2016, Wolters Kluwer Health

    Professor M Isabel Lucena

  6. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions

    Article • Drug Safety, July 2016, Springer Science + Business Media

    Professor M Isabel Lucena

  7. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury

    Article • Liver International, June 2016, Wiley

    Professor M Isabel Lucena, Thierry Poynard

  8. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population

    Article • The Lancet Diabetes & Endocrinology, June 2016, Elsevier

    Professor M Isabel Lucena

  9. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury

    Article • Journal of Hepatology, May 2016, Elsevier

    Professor M Isabel Lucena

  10. “Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge”

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2016, Informa Healthcare

    Professor M Isabel Lucena

  11. Correction: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort

    Article • PLoS ONE, October 2015, PLOS

    Professor M Isabel Lucena

  12. Clinical Networks And Consortia In Drug-Induced Liver Injury (Dili): An Opportunity For Advancing Safety Science

    Article • Clinical Therapeutics, August 2015, Elsevier

    Professor M Isabel Lucena

  13. Drug-induced liver injury: Interactions between drug properties and host factors

    Article • Journal of Hepatology, August 2015, Elsevier

    Professor M Isabel Lucena

  14. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity

    Article • Liver International, April 2015, Wiley

    Professor M Isabel Lucena, Dr Agustin Castiella

  15. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?

    Article • Journal of Hepatology, March 2015, Elsevier

    Professor M Isabel Lucena

  16. Reply

    Article • Gastroenterology, February 2015, Elsevier

    Professor M Isabel Lucena

  17. Editorial: showing due DILIgence - the lessons from anabolic steroids; authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, January 2015, Wiley

    Professor M Isabel Lucena

  18. Reply

    Article • Gastroenterology, December 2014, Elsevier

    Professor M Isabel Lucena

  19. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids

    Article • Alimentary Pharmacology & Therapeutics, November 2014, Wiley

    Professor M Isabel Lucena

  20. Mechanisms of drug-induced liver injury

    Article • Current Opinion in Allergy and Clinical Immunology, August 2014, Wolters Kluwer Health

    Professor M Isabel Lucena

  21. Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury

    Article • Gastroenterology, July 2014, Elsevier

    Professor M Isabel Lucena

  22. Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort

    Article • PLoS ONE, April 2014, PLOS

    Professor M Isabel Lucena

  23. Consumo de fármacos relacionados con el tratamiento de la diabetes mellitus y otros factores de riesgo cardiovascular en la población española. Estudio Di@bet.es

    Article • Revista Española de Cardiología, November 2013, Elsevier

    Professor M Isabel Lucena

  24. Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study

    Article • Revista Española de Cardiología (English Edition), November 2013, Elsevier

    Professor M Isabel Lucena

  25. HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity

    Article • PLoS ONE, July 2013, PLOS

    Professor M Isabel Lucena

  26. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury

    Article • Liver International, May 2013, Wiley

    Professor M Isabel Lucena

  27. Causality Assessment

    Article • January 2013, Elsevier

    Professor M Isabel Lucena

  28. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs

    Article • Pharmacogenetics and Genomics, November 2012, Wolters Kluwer Health

    Professor M Isabel Lucena

  29. Drugs prescription in patients with chronic liver disease: rules for adjusting doses and beyond

    Article • Revista Española de Enfermedades Digestivas, April 2012, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Professor M Isabel Lucena

  30. Genetic variations in drug-induced liver injury (DILI): resolving the puzzle

    Article • Frontiers in Genetics, January 2012, Frontiers

    Professor M Isabel Lucena

  31. Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology

    Article • Frontiers in Pharmacology, January 2012, Frontiers

    Professor M Isabel Lucena, Professor Lina Badimon

  32. Hepatotoxicity in 2011: advancing resolutely

    Article • Revista Española de Enfermedades Digestivas, September 2011, Instituto de Salud Carlos III/BNCS/SciELO Espana

    Professor M Isabel Lucena

  33. Causality assessment methods in drug induced liver injury: Strengths and weaknesses

    Article • Journal of Hepatology, September 2011, Elsevier

    Professor M Isabel Lucena

  34. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury

    Article • Hepatology, August 2011, Wiley

    Dr Agustin Castiella, Professor M Isabel Lucena

  35. Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury

    Article • Pharmacoepidemiology and Drug Safety, July 2011, Wiley

    Professor M Isabel Lucena

  36. Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles

    Article • Gastroenterology, July 2011, Elsevier

    Professor M Isabel Lucena

  37. Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge

    Article • Digestive Diseases and Sciences, June 2011, Springer Science + Business Media

    Dr Agustin Castiella, Professor M Isabel Lucena

  38. Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad

    Article • Gastroenterología y Hepatología, May 2011, Elsevier

    Professor M Isabel Lucena

  39. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity

    Article • Expert Opinion on Drug Metabolism & Toxicology, April 2011, Informa Healthcare

    Professor M Isabel Lucena

  40. Reflections on Running Training Workshops for Research Ethics Committee Members in Spain Between 2001 and 2008

    Article • Croatian Medical Journal, December 2010, Croatian Medical Journal

    Professor M Isabel Lucena

  41. Drug Induced Liver Disease: Mechanisms and Diagnosis

    Article • July 2010, Wiley

    Professor M Isabel Lucena

  42. Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment

    Article • Current Drug Safety, July 2010, Bentham Science Publishers

    Professor M Isabel Lucena

  43. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™

    Article • Drug Safety, June 2010, Springer Science + Business Media

    Professor M Isabel Lucena

  44. S1873 The use of Liver Biopsy Evaluation in Determination of Autoimmune Hepatitis vs. Drug-Induced Liver Injury

    Article • Gastroenterology, May 2010, Elsevier

    Dr Agustin Castiella, Professor M Isabel Lucena

  45. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury

    Article • Hepatology, March 2010, Wiley

    Professor M Isabel Lucena

  46. Toxicidad hepática inducida por los nuevos fármacos inmunosupresores

    Article • Gastroenterología y Hepatología, January 2010, Elsevier

    Professor M Isabel Lucena

  47. Rechallenge in drug-induced liver injury: the attractive hazard

    Article • Expert Opinion on Drug Safety, November 2009, Informa Healthcare

    Professor M Isabel Lucena

  48. Drug-induced liver injury: insights from genetic studies

    Article • Pharmacogenomics, September 2009, Future Medicine

    Professor M Isabel Lucena

  49. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection

    Article • Clinical Therapeutics, May 2009, Elsevier

    Professor M Isabel Lucena

  50. Reply:

    Article • Hepatology, April 2009, Wiley

    Professor M Isabel Lucena

  51. Corrigendum to “Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome” [J Hepatol 49 (2008) 107–114]

    Article • Journal of Hepatology, March 2009, Elsevier

    Professor M Isabel Lucena

  52. Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex

    Article • Hepatology, February 2009, Wiley

    Professor M Isabel Lucena

  53. Authors’ reply

    Article • Fundamental and Clinical Pharmacology, December 2008, Wiley

    Professor M Isabel Lucena

  54. GlutathioneS-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury

    Article • Hepatology, August 2008, Wiley

    Dr Agustin Castiella, Professor M Isabel Lucena

  55. Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome

    Article • Journal of Hepatology, July 2008, Elsevier

    Professor M Isabel Lucena

  56. Statins: Hepatic Disease and Hepatotoxicity Risk

    Article • The Open Gastroenterology Journal, June 2008, Bentham Science Publishers

    Professor M Isabel Lucena

  57. Assessment of drug-induced liver injury in clinical practice

    Article • Fundamental and Clinical Pharmacology, April 2008, Wiley

    Professor M Isabel Lucena

  58. Idiosyncratic drug hepatotoxicity: a 2008 update

    Article • Expert Review of Clinical Pharmacology, March 2008, Taylor & Francis

    Professor M Isabel Lucena

  59. Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review

    Article • Current Drug Safety, May 2007, Bentham Science Publishers

    Professor M Isabel Lucena

  60. Reply

    Article • Gastroenterology, May 2007, Elsevier

    Professor M Isabel Lucena

  61. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain

    Article • Hepatology, January 2006, Wiley

    Dr Agustin Castiella, Professor M Isabel Lucena

  62. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

    Article • Hepatology, January 2006, Wiley

    Professor M Isabel Lucena, Prof. Luis Rodrigo

  63. Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period

    Article • Gastroenterology, August 2005, Elsevier

    Professor M Isabel Lucena

  64. The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment

    Article • European Journal of Gastroenterology & Hepatology, January 2005, Wolters Kluwer Health

    Professor M Isabel Lucena

  65. Causality assessment in drug-induced hepatotoxicity

    Article • Expert Opinion on Drug Safety, July 2004, Informa Healthcare

    Professor M Isabel Lucena

  66. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease

    Article • Hepatology, May 2004, Wiley

    Professor M Isabel Lucena

  67. Hepatotoxicity Related to Citalopram

    Article • American Journal of Psychiatry, May 2004, American Psychiatric Association

    Professor M Isabel Lucena

  68. Severe toxic hepatitis related to chlormethiazole

    Article • Journal of Hepatology, December 2003, Elsevier

    Professor M Isabel Lucena, Prof. Luis Rodrigo

  69. Lansoprazole-Induced Hepatic Dysfunction

    Article • Annals of Pharmacotherapy, November 2003, SAGE Publications

    Professor M Isabel Lucena

  70. Hepatitis aguda por bentazepam

    Article • Medicina Clínica, May 2003, Elsevier

    Professor M Isabel Lucena

  71. Antidepressant-induced hepatotoxicity

    Article • Expert Opinion on Drug Safety, May 2003, Informa Healthcare

    Professor M Isabel Lucena

  72. Diez años de comités éticos de investigación clínica: los riesgos de la complacencia

    Article • Medicina Clínica, March 2003, Elsevier

    Professor M Isabel Lucena

  73. Hepatitis aguda por bentazepam

    Article • Medicina Clínica, January 2003, Elsevier

    Professor M Isabel Lucena

  74. Diez años de comités éticos de investigación clínica: los riesgos de la complacencia

    Article • Medicina Clínica, January 2003, Elsevier

    Professor M Isabel Lucena

  75. Antidepressant-induced hepatotoxicity

    Article • Expert Opinion on Drug Safety, January 2003, Informa Healthcare

    Professor M Isabel Lucena

  76. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis

    Article • European Journal of Clinical Pharmacology, September 2002, Springer Science + Business Media

    Professor M Isabel Lucena

  77. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity

    Article • European Journal of Gastroenterology & Hepatology, August 2002, Wolters Kluwer Health

    Professor M Isabel Lucena

  78. Chronic hepatitis C, ibuprofen, and liver damage

    Article • The American Journal of Gastroenterology, July 2002, Nature

    Professor M Isabel Lucena

  79. Hepatotoxicity Associated With the New Antidepressants

    Article • The Journal of Clinical Psychiatry, February 2002, Physicians Postgraduate Press, Inc

    Professor M Isabel Lucena

  80. Tetrabamato: un apunte sobre la relación beneficio-riesgo

    Article • Medicina Clínica, January 2002, Elsevier

    Professor M Isabel Lucena

  81. Riluzole-induced acute pancreatitis

    Article • The American Journal of Gastroenterology, July 2001, Nature

    Professor M Isabel Lucena

  82. Benzylpenicillin-Induced Prolonged Cholestasis

    Article • Annals of Pharmacotherapy, June 2001, SAGE Publications

    Professor M Isabel Lucena

  83. Benzylpenicillin-induced prolonged cholestasis

    Article • Annals of Pharmacotherapy, June 2001, SAGE Publications

    Professor M Isabel Lucena

  84. Fulminant liver failure associated with flutamide therapy for hirsutism

    Article • The Lancet, March 1999, Elsevier

    Professor M Isabel Lucena

  85. Norfloxacin-Induced Cholestatic Jaundice

    Article • The American Journal of Gastroenterology, November 1998, Nature

    Professor M Isabel Lucena

  86. Interaction of Fluoxetine and Valproic Acid

    Article • American Journal of Psychiatry, April 1998, American Psychiatric Association

    Professor M Isabel Lucena

  87. Acute Renal Failure Attributable to Ciprofloxacin in a Patient With the Acquired Immunodeficiency Syndrome

    Article • Archives of Internal Medicine, January 1995, American Medical Association (AMA)

    Professor M Isabel Lucena